Is Gennex Lab. overvalued or undervalued?

As of 6 November 2025, the valuation grade for Gennex Lab. has moved from attractive to very attractive. The company is currently considered undervalued based on its financial ratios, including a PE ratio of 19.73, an EV to EBITDA of 13.69, and a PEG ratio of 1.50. These metrics suggest that Gennex Lab. is positioned favorably compared to its peers in the pharmaceuticals and biotechnology sector.
In comparison to notable peers, Sun Pharma. has a significantly higher PE ratio of 35.02 and an EV to EBITDA of 10.54, indicating it is expensive relative to Gennex Lab. Additionally, Dr. Reddy's Labs, which is rated attractive, has a PE ratio of 17.42, further supporting the notion that Gennex Lab. is undervalued. Despite recent stock performance showing a decline of 33.84% over the past year, the long-term perspective remains strong, with a 5-year return of 297.50%, suggesting potential recovery and growth ahead.